Emyria

D4, 661 Newcastle Street
Leederville WA 6007

Home

Contact Us

Updates

Corporate Governance

Annual Reports

Share Price

Announcements

New investors

Why Invest in Emyria?

Investor Research

Loyalty Option Offer

Presentations

Successes

Meet the Team

About Emyria

Webinars

Montserrat

Emyria Limited

Emyria's recent update highlights the company's commitment to addressing Australia's mental health crisis through advanced therapies and compassionate care. As the only ASX-listed company offering direct care in this sector, Emyria is focused on expanding access to innovative treatments to enhance the lives of Australians. Leveraging Australia's unique legal access pathways, Emyria has successfully navigated multiple regulatory and clinical barriers to deliver world-leading treatment programs, supported by TGA-approved specialists and therapists.

The company's focus on tackling treatment-resistant PTSD and depression underscores its dedication to addressing prevalent mental health conditions with significant unmet needs. Through its dedicated medical centers and a team of experts, Emyria continues to deliver positive clinical outcomes while actively expanding its programs. Additionally, the company's readiness to launch its depression program, supported by TGA-approved prescribers and pharmacy-grade medicine, demonstrates its commitment to advancing mental health care.

Investor interest in psychedelic-assisted therapy is also on the rise, driven by evolving political landscapes that signal wider acceptance of these treatments. For further inquiries or to learn more about our initiatives, feel free to reach out to us.

Emyria's recent update highlights the company's commitment to addressing Australia's mental health crisis through advanced therapies and compassionate care. As the only ASX-listed company offering direct care in this sector, Emyria is focused on expanding access to innovative treatments to enhance the lives of Australians. Leveraging Australia's unique legal access pathways, Emyria has successfully navigated regulatory barriers to deliver world-leading treatment programs, supported by TGA-approved specialists and therapists.

The company's focus on tackling treatment-resistant PTSD and depression underscores its dedication to addressing prevalent mental health conditions with significant unmet needs. Through its dedicated medical centers and a team of experts, Emyria continues to deliver positive clinical outcomes while actively expanding its programs. Additionally, the company's readiness to launch its depression program, supported by TGA-approved prescribers and pharmacy-grade medicine, demonstrates its commitment to advancing mental health care.

Investor interest in psychedelic-assisted therapy is on the rise, driven by evolving political landscapes that signal wider acceptance of these treatments. Emyria's financial overview reflects the company's strategic position, with substantial shareholders and trading information demonstrating market confidence. For further inquiries or to learn more about our initiatives, feel free to reach out to us.

Investor Update - November 2024

Summary